AMS:BAI - Euronext Amsterdam - LU2355630455 - Common Stock - Currency: EUR
AMS:BAI (3/12/2025, 7:00:00 PM)
0.081
-0.01 (-14.74%)
The current stock price of BAI.AS is 0.081 EUR. In the past month the price decreased by -57.37%. In the past year, price decreased by -88.75%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 40.18 | 530.12B | ||
1LLY.MI | ELI LILLY & CO | 39.07 | 515.48B | ||
ZEG.DE | ASTRAZENECA PLC | 16.85 | 397.48B | ||
JNJ.DE | JOHNSON & JOHNSON | 17.19 | 356.82B | ||
RHO.DE | ROCHE HOLDING AG-BR | 13.13 | 221.90B | ||
SAN.PA | SANOFI | 11.02 | 202.87B | ||
SNW.DE | SANOFI | 10.81 | 199.09B | ||
1SAN.MI | SANOFI | 10.74 | 197.73B | ||
NOT.DE | NOVARTIS AG-REG | 13.52 | 197.11B | ||
NOV.DE | NOVO NORDISK A/S-B | 12.86 | 193.20B | ||
6MK.DE | MERCK & CO. INC. | 10.53 | 175.27B | ||
1MRKX.MI | MERCK & CO. INC. | 10.35 | 172.26B |
BenevolentAI SA is a holding company that engages in the research and development and sale of AI-enabled drugs. The firm designs its technology to enable scientists to better understand the development of disease mechanisms, discover drug targets and make decisions. The company serves patients by leveraging its proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop drugs for complex diseases. The Benevolent Platform integrates technology, processes, and humans for faster research and development success. Its pipeline includes BEN-8744, BEN-28010, BEN-34712, Parkinson's disease, and Fibrosis. BEN-8744 is developed for the treatment of an ulcerative colitis. The firm provides scientists with a view of disease biology by integrating across all the domains and diverse data types, including omics, molecules, experimental data, literature, pathology, and biological systems.
Odyssey Acquisition SA
4-8 Maple Street
London GB
Employees: 180
Phone: 442037819360
The current stock price of BAI.AS is 0.081 EUR. The price decreased by -14.74% in the last trading session.
The exchange symbol of Odyssey Acquisition SA is BAI and it is listed on the Euronext Amsterdam exchange.
BAI.AS stock is listed on the Euronext Amsterdam exchange.
5 analysts have analysed BAI.AS and the average price target is 2.75 EUR. This implies a price increase of 3300% is expected in the next year compared to the current price of 0.081. Check the Odyssey Acquisition SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
Odyssey Acquisition SA (BAI.AS) has a market capitalization of 11.58M EUR. This makes BAI.AS a Nano Cap stock.
Odyssey Acquisition SA (BAI.AS) currently has 180 employees.
The Revenue of Odyssey Acquisition SA (BAI.AS) is expected to decline by -31.89% in the next year. Check the estimates tab for more information on the BAI.AS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BAI.AS does not pay a dividend.
Odyssey Acquisition SA (BAI.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
ChartMill assigns a fundamental rating of 2 / 10 to BAI.AS. BAI.AS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months BAI.AS reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 33.78% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -54.61% | ||
ROE | -73.07% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 80% to BAI.AS. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 8.46% and a revenue growth -31.89% for BAI.AS